P53蛋白在胃癌与肠上皮化生中的表达和意义

目的:检测肠上皮化生的胃黏膜组织和胃癌组织中P53蛋白的表达,探讨其变化规律及意义。方法:选择收集送检胃癌的新鲜标本29例,取癌组织及癌旁4~5个点的组织,采取苏木素-伊红染色、黏液组织化学染色筛选肠上皮化生16例,应用免疫组织化学染色对胃癌组织和肠上皮化生黏膜的P53蛋白的表达进行研究。结果:肠上皮化生和胃癌组织中均有不同程度的P53蛋白表达,但与正常胃黏膜比较,P53蛋白表达由强到弱依次为:不完全性大肠型肠化→不完全性小肠型肠化→癌旁正常黏膜。结论:P53蛋白的表达不仅与肠上皮化生的类型有关,而且与胃上皮的异型增生程度密切相关。     

Evaluation of Full-length,Cleaved and Nitrosylated Serum Surfactant Protein D as Biomarkers for COPD

Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is characterized by partially reversible airflow obstruction. Serum surfactant protein D (SP-D) is synthesized by type II pneumocytes and Clara cells and participates in surfactant homeostasis and pulmonary host defense. Serum levels of SP-D are raised in individuals with COPD but there is no correlation between the serum level of SP-D and the severity of airflow obstruction. Serum SP-D is present in different forms that may have more utility as a biomarker for COPD. We report here the development of new monoclonal antibodies to full length and cleaved SP-D. We have assessed these and existing antibodies in 98 individuals with COPD recruited to the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Our data show that neither monoclonal antibodies to full length nor cleaved SP-D provide additional information over that obtained with a polyclonal antibody. Moreover, levels of serum nitrosylated-SP-D did not correlate with serum level of SP-D or any clinical phenotype of COPD. The measurement of modified SP-D is of limited value in characterising individuals with COPD.     

Novel airway findings in a patient with 1p36 deletion syndrome

1p36 deletion syndrome comprises a phenotypic presentation that includes central nervous system, cardiac, and craniofacial anomalies. There has been no report of associated airway anomalies with this syndrome. We present here a case report and literature review. Prenatally, amniocentesis for chromosomal analysis was performed on our patient, with results consistent with 1p36 deletion syndrome. Respiratory distress and unsuccessful attempts at intubation prompted transfer to Children's Hospital of Colorado. Microlaryngoscopy was subsequently performed, revealing a persistent buccopharyngeal membrane and unidentifiable larynx. Emergent tracheostomy was then performed to secure the airway. Airway anomalies may be associated with 1p36 deletion syndrome.     

MSCs来源外泌体在创面修复中的研究进展

目的总结近年来 MSCs 来源外泌体（exosomes，EXOs）在创面修复中的研究进展。方法广泛查阅国内外有关 MSCs-EXOs 在创面修复中作用的文献，总结分析 MSCs-EXOs 在创面修复过程中的作用机制及其临床应用前景。结果MSCs-EXOs 在创面愈合过程中可抑制早期的炎性反应，促进血管新生和上皮细胞的增殖与迁移，后期调控胶原合成并抑制瘢痕增生。与 MSCs 相比，MSCs-EXOs 具有高稳定性、易于储存、不易致瘤、无需增殖、便于定量使用等优点，有着广阔的临床应用前景。结论MSCs-EXOs 能够促进创面修复，且有希望发展成为临床上一种促进急性或慢性创面修复的产品。     

微小RNA-148a-3p靶向调控MAP3K9表达及对胃癌细胞增殖和凋亡的影响

目的 探讨微小RNA-148a-3p（miR-148a-3p）对丝裂原活化蛋白激酶激酶激酶9（MAP3K9）的靶向调控作用及对胃癌细胞增殖和凋亡的影响。方法 向对数生长期胃癌细胞株MGC-803转染miR-148a-3p模拟物（mimics组）和阴性对照（NC组），以未转染的MGC-803细胞为对照组；采用实时定量PCR（QPCR）检测各组miR-148a-3p水平以评价转染效率，MTT法检测各组细胞增殖能力，流式细胞术检测各组细胞凋亡情况，分别采用QPCR和Western blotting检测Bcl-2、Bax、caspase-3及MAP3K9 mRNA和蛋白水平，同时采用双荧光素酶报告实验验证miR-148a-3p与MAP3K9的靶向作用关系。结果 QPCR结果显示，对照组、NC组和mimics组的miR-148a-3p水平分别为1.021±0.123、1.087±0.196和2.854±0.368，与对照组和NC组比较，mimics组的miR-148a-3p水平升高（P＜0.05）。mimics组MGC-803细胞的增殖活力较其余两组减弱（P＜0.05）。mimics组MGC-803细胞凋亡率为（15.2±1.6）％，高于对照组的（3.5±0.9％）％和NC组的（4.5±1.1）％，差异具有统计学意义（P＜0.05）。与对照组和NC组比较，mimics组的MAP3K9和Bcl-2的mRNA和蛋白水平均下调，而Bax和caspase-3的mRNA和蛋白水平均上调（P＜0.05）；双荧光素酶报告实验证实MAP3K9是miR-148a-3p的直接作用靶点。结论 MiR-148a-3p可抑制胃癌细胞MGC-803的增殖并诱导其凋亡，可能通过靶向MAP3K9来发挥抑癌作用，调控miR-148a-3p／MAP3K9轴在胃癌防治中有一定应用前景。